| 產品編號 | bs-13129R-PE-Cy5.5 |
| 英文名稱 | Rabbit Anti-FACL4/PE-Cy5.5 Conjugated antibody |
| 中文名稱 | PE-Cy5.5標記的酰基輔酶A合成酶4抗體 |
| 別 名 | ACS 4; ACS4; ACSL 4; Acsl4; ACSL4_HUMAN; acyl CoA synthetase 4; Acyl CoA synthetase long chain family member 4; FACL 4; FACL4; Fatty acid Coenzyme A ligase; fatty acid Coenzyme A ligase long-chain 4; LACS 4; LACS4; Lignoceroyl CoA synthase; Long chain 4; long chain acyl CoA synthetase 4; long chain fatty acid CoA ligase 4; long chain fatty acid Coenzyme A ligase 4; Long-chain acyl-CoA synthetase 4; Long-chain-fatty-acid--CoA ligase 4; MRX63; MRX68. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 細胞生物 發育生物學 神經生物學 信號轉導 新陳代謝 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, Chicken, Pig, Cow, Horse, Rabbit, Sheep, ) |
| 產品應用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 79kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human FACL4/ACSL4 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: Acyl-CoA synthetases, also known as long-chain fatty-acid CoA synthases (FACL) or palmitoyl-CoA ligases, include ACSL1-6, which are all single-pass membrane proteins localizing to the mitochondrion, microsome or peroxisome. FACL proteins are important for synthesis of cellular lipids and for ∫-oxidation degradation. Specifically, ACSL proteins catalyze the activation of long-chain fatty acids to acyl-CoAs, which can be metabolized to form CO2, triacylglycerol (TAG), phospholipids (PL) and cholesteryl esters (CE). ACSL3 preferentially utilizes laurate, myristate, arachidonate and eicosapentaenoate among saturated and unsaturated long chain fatty acids. FACL3 is expressed as two isoforms in various tissues, including brain, heart, placenta, prostate, skeletal muscle, testis and thymus. FACL4 preferentially utilizes arachidonate and is abundant in steroidogenic tissues. FACL4 may modulate female fertility and uterine prostaglandin production. Function: Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses arachidonate and eicosapentaenoate as substrates. Subcellular Location: Mitochondrion outer membrane. Peroxisome membrane. Microsome membrane. Endoplasmic reticulum membrane. DISEASE: Defects in ACSL4 are the cause of mental retardation X-linked type 63 (MRX63) [MIM:300387]. Mental retardation is a mental disorder characterized by significantly sub-average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. Non-syndromic mental retardation patients do not manifest other clinical signs. Defects in ACSL4 are involved in Alport syndrome with mental retardation midface hypoplasia and elliptocytosis (ATS-MR) [MIM:300194]. A X-linked contiguous gene deletion syndrome characterized by glomerulonephritis, deafness, mental retardation, midface hypoplasia and elliptocytosis. Similarity: Belongs to the ATP-dependent AMP-binding enzyme family. Database links: Entrez Gene: 2182 Human Entrez Gene: 50790 Mouse Omim: 300157 Human SwissProt: O60488 Human SwissProt: Q9QUJ7 Mouse Unigene: 268785 Human Unigene: 391337 Mouse Unigene: 87821 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
